WHWilliam G. Hodge

William G. Hodge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William G. Hodge has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tranexamic acid in the treatment of pediatric traumatic hyphema.

    by David A Albiani, William G Hodge, Y Irene Pan, Todd E Urton, William N Clarke

    This study was undertaken to determine whether a difference exists in treatment outcome between patients treated with tranexamic acid (TEA) plus topical steroids and those treated with topical steroids alone. A retrospective cohort study was conducted to compare treatment results for children with traumatic hyphema treated with TEA and topical steroids versus topical steroids alone. Patients were identified from a chart review of the Children's Hospital of Eastern Ontario eye clinic and the Queen's Department of Ophthalmology emergency eye clinic for charts coded "traumatic hyphema." The primary outcomes measured included visual acuity, rebleed rate, intraocular pressure, and time to hyphema resolution. Covariates were hyphema grade, the need for medications to lower intraocular pressure, and the presence of associated ocular traumatic complications. Analysis was performed with both bivariate analysis and multivariate models. Two hundred and fifteen patients with traumatic hyphema were included in our study. One hundred and thirty-seven patients (63.1%) received TEA plus topical steroids, and the remaining 78 patients received topical steroids alone. There was no significant difference in rebleed rate between the TEA plus topical steroid group (1.6%) and the steroid-alone group (2.6%, p = 0.60). Patients with traumatic hyphema treated with TEA plus topical steroids did not have a significantly lower incidence of rebleed than those treated with topical steroids alone.


  • Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis

    by Jean Lachaine, William G. Hodge, Isabella Steffensen, Christine Murray, David Barnes, Vicki Foerster, Thierry Ducruet, Shaila Mensinkai


  • The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review

    by W G Hodge, J Lachaine, I Steffensen, C Murray, D Barnes, V Foerster, T Ducruet, A Morrison

    Aim: To systematically review the literature on the efficacy and harm of prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in treating elevated intraocular pressure (IOP). Methods: Keywords were searched in major literature databases to identify relevant randomised clinical trials (RCTs) of PGAs for ophthalmic use. The study quality of RCTs was assessed using the Jadad scale. Outcomes assessed included reduction in IOP in individual patients, adverse events (AEs) and withdrawals due to AEs. Results: Eight unique RCTs evaluating a total of 1,722 individuals were included in this systematic review. Analysis did not show a significant reduction in the mean IOP from patients receiving latanoprost compared with those receiving brimonidine (WMD = −1.04; p = 0.30). On the other hand, the latanoprost group showed a significant reduction in mean IOP compared to the dorzolamide group (WMD = −2.64; pConclusion: Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. Neither travoprost nor bimatoprost was compared to dorzolamide or brimonidine in the present literature.


  • Open Access

    The consequences of waiting for cataract surgery: a systematic review

    by William Hodge, Tanya Horsley, David Albiani, Julia Baryla, Michel Belliveau, Ralf Buhrmann, Michael O'Connor, Jason Blair, Elizabeth Lowcock

    Background: Cataract surgery is the most common operative procedure performed in Canada, and how patients are affected by wait times for this surgery has important clinical, public health and health policy considerations. We conducted a systematic review to understand the relation between wait time for cataract surgery and patient outcomes and the variables that modify this relation. Methods: We performed an electronic search of 11 databases and the proceedings of 4 conferences. The search was restricted to studies published after the transition to phacoemulsification (1990). We assessed the quality of the included studies using the Jadad Scale for randomized controlled trials and the Newcastle–Ottawa Scale for cohort and case–control studies. The data were found to be inappropriate for meta-analysis, thus we performed a qualitative synthesis. Results: We found a total of 27 studies that met our inclusion criteria. When these studies were reviewed, a dichotomy was observed for the wait time–outcome relation: outcomes associated with wait times of ≤ 6 weeks were better than outcomes associated with wait times of ≥ 6 months. Patients who waited more than 6 months to receive cataract surgery experienced more vision loss, a reduced quality of life and had an increased rate of falls compared with patients who had wait times of less than 6 weeks. The outcomes associated with wait times between 6 weeks and 6 months remain unclear. Interpretation: Patients who wait more than 6 months for cataract surgery may experience negative outcomes during the wait period, including vision loss, a reduced quality of life and an increased rate of falls.


  • EVIDENCE FOR THE EFFECT OF Ω-3 FATTY ACIDS ON PROGRESSION OF AGE-RELATED MACULAR DEGENERATION

    by William G. Hodge, David Barnes, Howard M. Schachter, Yi Irene Pan, Elizabeth C. Lowcock, Li Zhang, Margaret Sampson, Andra Morrison, Khai Tran, Maia Miguelez, et al.

    As part of a larger systematic review on the effect of ω-3 fatty acids on eye health, the aim of this report was to appraise and synthesize the evidence for the effects of ω-3 fatty acids in slowing down the progression of age-related macular degeneration (AMD) and/or decreasing the rate of progression to advanced forms of AMD. A comprehensive search was undertaken in six databases (MEDLINE, PreMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, CAB Health, and Dissertation Abstracts). Two unique studies, one randomized clinical trial (RCT) and one prospective cohort study, satisfied the eligibility criteria and were included in the review. The RCT reported evidence on the effect of ω-3 fatty acids in slowing down the progression of AMD. The prospective cohort study addressed the question: what is the evidence that ω-3 fatty acids decrease the rate of progression to advanced forms of AMD? Clinical research on this topic is scarce. Only two studies were eligible to be included in this review. Although one study result indicated efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research.


  • Long-Term Efficacy of Phototherapeutic Keratectomy on Recurrent Corneal Erosion Syndrome

    by J Bsc Baryla, Y I Pan, W G MD Hodge

    Purpose: To assess the long-term sequelae, principally time-to-first-recurrence, of phototherapeutic keratectomy (PTK) for the treatment of recurrent corneal erosion syndrome (RCES). Methods: A retrospective case series was performed. Thirty-nine eyes in 33 patients with RCES required PTK and were treated using the VISX STAR Excimer Laser System. The data were analyzed with the Kaplan-Meier survival estimate. Results: Patients were characterized by the cause of their RCES. More than 50% had epithelial corneal dystrophies, 31% were posttraumatic, and 15% were idiopathic. Overall, 25% of eyes had a recurrence by 3 months, and 36% had a recurrence by 9 months. The mean follow-up time was 17.4 months (range, 0.4-67.6 months). Of those who had a primary recurrence, 38% had a second and 15% had a third. Visual acuity was slightly decreased within 2 weeks after surgery, and 10% of patients developed transient haze. No serious adverse effects were reported. Conclusion: PTK is an important treatment of RCES refractory to other therapies. Long-term data suggest that most patients treated with PTK do not develop recurrences, and side effects from PTK are minimal.


  • The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review

    by William G. Hodge, David Barnes, Howard M. Schachter, Yi I. Pan, Elizabeth C. Lowcock, Li Zhang, Margaret Sampson, Andra Morrison, Khai Tran, Maia Miguelez, et al.


  • Efficacy of ω-3 Fatty Acids in Preventing Age-Related Macular Degeneration

    by William G. Hodge, Howard M. Schachter, David Barnes, Yi Pan, Elizabeth C. Lowcock, Li Zhang, Margaret Sampson, Andra Morrison, Khai Tran, Maia Miguelez, et al.


  • Iatrogenic risk factors for cytomegalovirus retinitis

    by William G. Hodge, Jean-François Boivin, Stanley H. Shapiro, Richard G. Lalonde, Kirtida C. Shah, Bradley D. Murphy, Michel A. Dionne, Aashish Goela